|
🐜
|
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.
15 auth.
A. Carracedo,
Li Ma,
J. Teruya-Feldstein,
F. Rojo,
L. Salmena,
A. Alimonti,
Ainara Egia,
A. Sasaki,
G. Thomas,
S. Kozma,
...
Antonella Papa,
C. Nardella,
L. Cantley,
J. Baselga,
P. Pandolfi
|
10 |
2008 |
10
🐜
|
|
🐬
|
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
M. Molina,
J. Codony-Servat,
J. Albanell,
F. Rojo,
J. Arribas,
J. Baselga
|
9 |
2001 |
9
🐬
|
|
🐜
|
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
11 auth.
M. Scaltriti,
F. Rojo,
A. Ocaña,
J. Anido,
M. Guzman,
J. Cortés,
...
S. Di Cosimo,
X. Matías-Guiu,
S. Ramón y. Cajal,
J. Arribas,
J. Baselga
|
9 |
2007 |
9
🐜
|
|
🐜
|
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
15 auth.
J. Baselga,
D. Rischin,
M. Ranson,
H. Calvert,
E. Raymond,
D. Kieback,
S. Kaye,
L. Gianni,
A. Harris,
T. Björk,
...
S. Averbuch,
A. Feyereislova,
H. Swaisland,
F. Rojo,
J. Albanell
|
9 |
2002 |
9
🐜
|
|
🐜
|
PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization
7 auth.
I. Shin,
F. Yakes,
F. Rojo,
N. Shin,
Andrei V Bakin,
J. Baselga,
...
C. Arteaga
|
9 |
2002 |
9
🐜
|
|
🐜
|
A SNAIL1–SMAD3/4 transcriptional repressor complex promotes TGF-β mediated epithelial–mesenchymal transition
15 auth.
T. Vincent,
E. Neve,
Jill R. Johnson,
A. Kukalev,
F. Rojo,
J. Albanell,
K. Pietras,
I. Virtanen,
L. Philipson,
P. Leopold,
...
R. Crystal,
A. G. Herreros,
A. Moustakas,
R. Pettersson,
J. Fuxe
|
9 |
2009 |
9
🐜
|
|
🐜
|
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
12 auth.
R. Herbst,
A. Maddox,
M. Rothenberg,
E. Small,
E. Rubin,
J. Baselga,
...
F. Rojo,
W. Hong,
H. Swaisland,
S. Averbuch,
J. Ochs,
P. LoRusso
|
9 |
2002 |
9
🐜
|
|
🐜
|
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.
20 auth.
J. Tabernero,
F. Rojo,
E. Calvo,
H. Burris,
I. Judson,
K. Hazell,
E. Martinelli,
S. Ramón y. Cajal,
Suzanne F. Jones,
L. Vidal,
...
N. Shand,
T. Macarulla,
F. J. Ramos,
S. Dimitrijević,
U. Zoellner,
Pui Tang,
M. Stumm,
H. Lane,
D. Lebwohl,
J. Baselga
|
9 |
2008 |
9
🐜
|
|
🐜
|
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.
12 auth.
J. Albanell,
F. Rojo,
S. Averbuch,
A. Feyereislova,
J. Mascaró,
R. Herbst,
...
P. LoRusso,
D. Rischin,
S. Sauleda,
J. Gee,
R. Nicholson,
J. Baselga
|
9 |
2002 |
9
🐜
|
|
🐜
|
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothe
109 auth.
S. Hendry,
R. Salgado,
T. Gevaert,
P. Russell,
T. John,
T. John,
B. Thapa,
M. Christie,
K. V. D. Vijver,
M. V. Estrada,
Paula I. Gonzalez-Ericsson,
M. Sanders,
B. Solomon,
C. Solinas,
G. V. D. Eynden,
...
Y. Allory,
Y. Allory,
M. Preusser,
J. Hainfellner,
G. Pruneri,
A. Vingiani,
S. Demaria,
F. Symmans,
P. Nuciforo,
L. Comerma,
E. Thompson,
S. Lakhani,
S. Lakhani,
Seong-Rim Kim,
S. Schnitt,
C. Colpaert,
C. Sotiriou,
S. Scherer,
M. Ignatiadis,
S. Badve,
R. Pierce,
G. Viale,
N. Sirtaine,
F. Penault-Llorca,
Tomohagu Sugie,
S. Fineberg,
S. Paik,
A. Srinivasan,
A. Richardson,
Yihong Wang,
Yihong Wang,
E. Chmielik,
J. Brock,
Douglas B. Johnson,
J. Balko,
S. Wienert,
V. Bossuyt,
S. Michiels,
N. Ternès,
N. Burchardi,
S. Luen,
S. Luen,
P. Savas,
P. Savas,
F. Klauschen,
P. Watson,
B. Nelson,
B. Nelson,
C. Criscitiello,
S. O'toole,
D. Larsimont,
R. Wind,
G. Curigliano,
F. André,
M. Lacroix-Triki,
Mark van de Vijver,
F. Rojo,
G. Floris,
S. Bedri,
J. Sparano,
D. Rimm,
T. Nielsen,
Z. Kos,
S. Hewitt,
Baljit Singh,
G. Farshid,
S. Loibl,
K. Allison,
N. Tung,
S. Adams,
K. Willard-Gallo,
H. Horlings,
L. Gandhi,
L. Gandhi,
Andre Moreira,
F. Hirsch,
M. Dieci,
M. Urbanowicz,
I. Brčić,
Konstanty Korski,
F. Gaire,
H. Koeppen,
A. Lo,
A. Lo,
J. Giltnane,
M. Rebelatto,
K. Steele,
J. Zha,
K. Emancipator,
J. Juco,
C. Denkert,
J. Reis-Filho,
S. Loi,
S. Fox
|
8 |
2017 |
8
🐜
|
|
🐜
|
High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.
11 auth.
A. Bruna,
R. Darken,
F. Rojo,
A. Ocaña,
S. Peñuelas,
A. Arias,
...
R. París,
A. Tortosa,
J. Mora,
J. Baselga,
J. Seoane
|
8 |
2007 |
8
🐜
|
|
🐢
|
Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.
12 auth.
J. Baselga,
J. Albanell,
A. Ruíz,
A. Lluch,
P. Gascón,
V. Guillem,
...
S. González,
S. Sauleda,
I. Marimón,
J. Tabernero,
M. Koehler,
F. Rojo
|
8 |
2005 |
8
🐢
|
|
🐜
|
Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.
28 auth.
M. Dieci,
N. Radosevic-Robin,
S. Fineberg,
G. G. Van den Eynden,
N. Ternès,
F. Penault-Llorca,
G. Pruneri,
Timothy D’alfonso,
S. Demaria,
C. Castañeda,
Joselyn Sanchez,
S. Badve,
S. Michiels,
V. Bossuyt,
F. Rojo,
...
Baljit Singh,
T. Nielsen,
G. Viale,
Seong-Rim Kim,
S. Hewitt,
S. Wienert,
S. Loibl,
D. Rimm,
F. Symmans,
C. Denkert,
S. Adams,
S. Loi,
R. Salgado
|
8 |
2017 |
8
🐜
|
